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Background: Syndromes of iron overload have been shown to increase the risk of severe clinical disease in
viral infections. Immune dysfunction is similarly described in hereditary haemochromatosis (HH). We
present here the case of a 51-year-old man who developed severe coronavirus disease 2019 (COVID-
19) complicated by suspected haemophagocytic lymphohistiocytosis (HLH). He was found to have HH
post-mortem and we propose a link between his iron overload and the development of severe COVID-19.
Case report: The initial clinical presentation consisted of cough, shortness of breath and fever.
Pancytopenia, markedly elevated ferritin and d-dimer were present. Computed tomography (CT) showed
bilateral ground glass changes consistent with COVID-19, widespread lymphadenopathy and splenome-
galy. A subsequent combined nose and throat swab was positive for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). HLH was suspected based upon the H-score and Anakinra, an IL-1 receptor
antagonist, was commenced. Liver function acutely worsened and magnetic resonance cholangiopancre-
atography (MRCP) revealed hepatic haemosiderosis. Intense splenic and cervical lymph node uptake were
seen on a positron emission tomography (PET) scan and high doses of intravenous steroids were admin-
istered due to concerns over haematological malignancy.
Results: Day fourteen of admission heralded the start of progressive clinical deterioration with rapid
increase in oxygen demands. Continuous positive airway pressure (CPAP) was trialled without success
and the patient unfortunately died seventeen days into admission. Results returned after his death
showed homozygous C282Y mutation of the HFE gene consistent with a diagnosis of HH. Post-mortem
examination revealed widespread haemosiderin deposition in the liver along with lung pathology in
keeping with severe COVID-19 and widespread splenic infarctions.
Conclusion: An association between HH and COVID-19 is not currently described in the literature. What
does exist, however, is an evidence base for the detrimental impacts iron overload has on viral infections
in general and the negative effects of HH on the immune system. We therefore postulate that the under-
lying metabolic and immune disturbances seen in HH should be considered a potential risk factor for the
development of severe COVID-19. This case also adds to the evidence that hyperinflammation appears to
be a unique and interesting characteristic of this novel viral disease.
 2020 Published by Elsevier Ltd on behalf of British Infection Association. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The key role of iron in viral infections is well described,
although not fully understood. Iron is an essential factor for suc-
cessful viral replication within living hosts and replete intracellular
iron stores provide favourable conditions for this process [1,2].
Excess iron is known to increase the risk of severe clinical
disease and worsen prognosis in several viral illnesses [2].
Table 1
Haematology laboratory results throughout admission.
Fig. 1. Radiology images throughout admission. (a) chest X-ray from day one of admission reported as showing mild right basal consolidation and hilar lymphadenopathy. (b)
Axial view of CT chest from day two of admission showing bilateral ground glass opacities. (c) Coronal view of PET scan showing intense diffuse FDG uptake in the spleen. (d)
coronal view of PET scan showing increased FDG uptake in cervical lymph nodes.
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load with a link to several immune defects and autoimmune
conditions [3]. We present the case of a 51-year-old male who
developed severe, ultimately fatal, coronavirus disease 2019
(COVID-19) complicated by suspected haemophagocytic lympho-
histiocytosis (HLH). He was subsequently found to have undiag-
nosed hereditary haemochromatosis (HH) post-mortem and we
hypothesise a link between his iron overload and the develop-
ment of severe COVID-19.2
Case
This 51-year-old man presented with a one-week history of
worsening shortness of breath, persistent dry cough and pyrexia.
He had a past medical history of an episode of community acquired
pneumonia in 2018 requiring a short hospital admission. He was
not taking any regular medications, consumed around 80 units of
alcohol per week, smoked 5–10 cigarettes per day and had a nor-
mal body mass index.
Graph 1. Trend in LFTs and HLH markers throughout admission.
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diced with non-tender hepatomegaly palpable 1 cm below the
costal margin. Investigations revealed pancytopenia (table 1) with
a mildly elevated bilirubin and gamma-glutamyl transferase (GGT).
Ferritin was 21,095 lg/l (reference range 30–400 lg/l), D-dimer
13,344 ng/ml (reference range 0–500 ng/ml) and transferrin satu-
ration 100%. HIV, hepatitis B and C screening were negative. EBV
serology was IgG positive, but IgM negative. Blood film showed
reactive changes with no immature forms and blood cultures were
negative.
Admission chest X-ray showed mild right basal consolidation
with hilar lymphadenopathy (Fig. 1a). Computed tomography
(CT) was reported as showing lymphadenopathy in the neck, tho-
rax and upper abdomen as well as bilateral ground glass opacities
in the upper lobes of the lungs (Fig. 1b), sclerotic bony lesions in
the spine and iliac bones, and likely splenic infarcts. The CT report
was concluded as being concerning for haematological malignancy
and COVID-19. Transthoracic echocardiogram showed no valvular
abnormality or evidence of endocarditis and three sets of repeat
blood cultures were negative.
Swabs taken on day one and three of admission were negative
by RT-PCR for SARS-CoV-2. However, these initial swab results
were felt to represent false negatives given the strong suspicion
of COVID-19 based on his clinical presentation, admission imaging
and community transmission dynamics. A further third combined
nose and throat swab was taken on day ten of admission and
was positive. The patient was treated with one day of oral
amoxicillin-clavulanic acid 625 mg, followed by a five-day course
of intravenous piperacillin-tazobactam 4.5 g three times a day.
HLH was suspected (H-score [4] on day two of admission sug-
gested a 96–98% probability) and Anakinra, an IL-1 receptor antag-
onist, was administered at a dose of 100 mg once a day for six days.
He also received a total of eight days intravenous methylpred-3
nisolone 800–1000 mg in addition to six days of oral prednisolone
50–75 mg. Over the course of the admission two bone marrow tre-
phine biopsies were performed showing evidence of dysplasia but
no clear evidence of haemophagocytosis or malignancy.
Liver function tests (LFTs) began to deteriorate on day five of
admission. At this point he had completed five days of antibiotics
and three days of Anakinra, suggesting potential drug induced hep-
atotoxicity. Clinically, biochemically and radiologically there were
no features of chronic liver disease nor features of portal hyperten-
sion. Peak LFTs were: bilirubin 346 lmol/l, alanine transaminase
(ALT) 161 u/l, GGT 624 u/l and alkaline phosphatase (ALP) 256 u/
l (graph 1). Serum albumin was mildly reduced throughout admis-
sion from a normal baseline; 24 g/l at its lowest. Ultrasound
demonstrated an enlarged fatty liver with normal ducts and sple-
nomegaly of 20 cm. MRCP was advised by the hepatology team
to further characterise the liver parenchyma given the uncertainty
regarding the aetiology of his liver dysfunction. This was per-
formed on day thirteen revealing hepatic haemosiderosis and
follow-up investigations were arranged. A PET scan was performed
after discussion with radiology to further investigate the tonsillar
mass identified on prior imaging and look for evidence of possible
malignancy. It demonstrated intense fluorodeoxyglucose (FDG)
uptake in the spleen (Fig. 1c) and cervical lymph nodes (Fig. 1d).
The bone lesions seen on CT were not PET-positive and were
deemed to be benign after further discussion with a specialist radi-
ologist. Further radiology opinion regarding the splenic findings
concluded that they would be in keeping with a hyperinflamma-
tory syndrome given the diffuse intense uptake. Unfortunately, a
planned cervical lymph node biopsy was ultimately not possible
due to significant interval reduction in lymphadenopathy, likely
secondary to parenteral steroid and Anakinra administration.
Repeat chest radiography on day eleven showed increasing
diffuse bilateral consolidation, typical of COVID-19. Progressive
Fig. 2. Microscopic appearances of liver tissue from post-mortem. (a and b) Diffuse haemosiderin deposition in hepatocytes and patchy fatty changes (haematoxylin and
eosin stain). (c) Pearl’s stain highlights haemosiderin deposition.
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twenty-one of symptoms) with the patient becoming increasingly
hypoxic, requiring 10–15 litres/minute of oxygen by a non-
rebreathe mask. He was trialled with CPAP but showed no
improvement, became progressively encephalopathic and unfortu-
nately passed away on day seventeen of admission.
Approximately three weeks following his death, results of
genetic testing were returned that revealed a homozygous C282Y
mutation of the Human Homeostatic Iron Regulator (HFE) gene.
This was deemed confirmatory of a diagnosis of hereditary
haemochromatosis in combination with a serum ferritin level of
21,095 ug/l, transferrin saturation of 100% and iron excess within
the liver identified on both MRCP and at post-mortem.
A post-mortem was performed given the complexity of his
admission and the unclear picture surrounding potential intercur-
rent malignant disease. The liver showed extensive deposition of
haemosiderin in hepatocytes consistent with hereditary
haemochromatosis (Fig. 2a–c) and fatty changes consistent with
a history of alcohol excess (Fig. 2b). There was no macroscopic or
microscopic evidence of hepatic cirrhosis. Post-mortem histology
of the liver also showed fibrous expansion of portal areas and occa-
sional fine fibrous bridging consistent with Ishak stage 3/6. The
lungs were congested and oedematous. Lung histology showed
acute diffuse alveolar damage with formation of hyaline mem-
branes (Fig. 3a) and bronchiolar fibrin (Fig. 3c). Occasional small
fibrin thrombi were also present (Fig. 3b). The findings are consis-
tent with COVID-19. The spleen showed two wedge shaped infarc-
tions (Fig. 4a and b) and widespread small foci of necrosis (Fig. 4c).
Few blood vessels adjacent to areas of infarctions showed intimal4
haemorrhage and intimal lymphocytic inflammatory cell infiltrate
(Fig. 5c and d) however, the significance of the vascular changes in
the spleen is uncertain due to the extensive necrosis. There was no
evidence of neoplasia including lymphoma. Only reactive hilar
lymph nodes were identified. There was no lymphadenopathy else-
where. The kidneys showed occasional glomerular and peritubular
capillary thrombi (Fig. 5a and b). There was no evidence of haemo-
siderin deposition in other organs.Discussion
The case that we present had an atypical COVID-19 clinical
course and the patient’s underlying diagnosis of hereditary
haemochromatosis may have predisposed him to developing sev-
ere bi-phasic manifestations of COVID-19 and subsequent fatal
outcome.
Hereditary haemochromatosis results in the accumulation of
iron in essential organs. This pathological process results from
the over-absorption of iron from the intestine and can lead to pro-
gressive end-organ damage [5]. HH can be associated with several
different mutations but most commonly the C282Ymutation of the
HFE gene. This mutation leads to abnormal structure of the HFE
protein which, under normal circumstances, is expressed ubiqui-
tously on cell surfaces. Wild-type HFE acts as an iron ‘sensor’ and
negatively regulates iron uptake, as well as regulating the produc-
tion of the hormone hepcidin [6]. Loss of structural integrity of the
mutant HFE protein results in reduced expression on the extracel-
lular surface and causes cellular uptake of iron to increase [7].
Fig. 3. Microscopic appearances of lung tissue from post-mortem. (a) Hyaline membranes in alveoli. (b) Fibrin thrombus in a capillary, congestion and alveolar haemorrhage.
(c) Accumulation of fibrin in a bronchiole and epithelial reactive metaplasia (haematoxylin and eosin stain).
M.J. Riley, S.R. Hicks, S. Irvine et al. Clinical Infection in Practice 7–8 (2020) 100052Secondary effects include the partial or complete loss of hepcidin
production resulting in reduced macrophage iron storage and
increased iron in the bloodstream [3]. Due to low penetrance, clin-
ical disease does not occur in all individuals with this mutation.
Conditions like haemochromatosis compromise host defence
mechanisms, and predispose to infection, autoimmune conditions
and some cancers. It has been demonstrated that low levels of hep-
cidin may be associated with an increased susceptibility to infec-
tion [8]. There is also increasing evidence of a direct link
between immune function and HH, with the HFE protein existing
at the interface between the immune system and iron metabolism
[3]. This relates, in part, to the similarity between the structure of
the HFE protein and major histocompatibility complex (MHC) class
I molecules. Individuals with HH have been shown to have defec-
tive cellular antigen presentation secondary to reduced MHC class
I molecule cell surface expression [9]. This may have implications
for mounting an initial host immune response to invading
pathogens.
Abnormal T lymphocyte function is also well described in HH
and can arise from a multitude of interferences, most significantly
affecting CD8 T lymphocytes. Defects in CD8 T lymphocyte differ-
entiation is thought to be one such example which results in
reduced numbers of circulating and hepatic CD8 T lymphocytes
in these patients [10]. Additional abnormalities in HH include
diminished T cell activation and signalling, as well as reduced cyto-
toxic capacity of cytotoxic T lymphocytes [3]. Direct effects from
excess iron can also negatively impact the immune system, mani-
festing as inhibited surface expression of adhesion molecules and
the CD4 co-receptor on T lymphocytes [3].
Bacteria, fungi and viruses have been shown to have increased
growth with excess levels of iron [11,12]. Viruses depend on iron5
in order to efficiently replicate within living host cells. It has been
shown that iron overload in human immunodeficiency virus (HIV),
hepatitis B (HBV) and hepatitis C (HCV) is a risk factor for severe
disease and increased mortality. Homozygous and heterozygous
mutations in HFE C282Y have been shown to cause hepatic iron
overload promoting steatosis and liver fibrosis in HCV-infected
patients [1]. It has been further suggested that limiting iron avail-
ability to infected cells by using iron chelators could be a beneficial
therapy in viral infections [2].
In this case the clinical presentation, laboratory results and
post-mortem findings are certainly in keeping with a syndrome
on the hyperinflammatory spectrum. This encompasses both
HLH and macrophage activation syndrome (MAS). Despite the
absence of confirmatory bone marrow diagnosis, it is important
to note that haemophagocytosis is not always demonstrated in
patients with HLH and MAS and its absence does not exclude
diagnosis [13,14]. Hyperinflammation appears to be the common
link between HLH and MAS, as opposed to haemophagocytosis
[15]. As such, utilising diagnostic criteria that consider the clin-
ical picture without relying solely on tissue diagnosis is impor-
tant. The diagnosis of HLH in adults is based on the HLH-2004
diagnostic criteria in conjunction with clinical judgment. Patients
need to meet  5 of 8 diagnostic criteria [16]. However due to
this patient’s underlying haemochromatosis the ferritin level
would have been elevated making the score less reliable. It is
difficult to consider the association of this acute COVID-19 ill-
ness with pancytopenia, deranged liver enzymes, elevated LDH,
hyperferritinaemia, splenomegaly and widespread lym-
phadenopathy without inferring a syndrome of significant
immune dysregulation. Treatment of MAS-HLH often includes
high-dose pulse methylprednisolone, cyclosporine A can be
Fig. 4. Macroscopic and microscopic appearances of splenic tissue from post-mortem. (a and b) Enlarged spleen and cut section showing wedge shaped infarction and several
small foci of necrosis. (c) Several foci of necrosis in the spleen with marked haemorrhage and congestion in the adjacent splenic parenchyma (haematoxylin and eosin stain).
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well as IL-1–blocking therapy with anakinra. Experience with
anti–IL-6 blockade with tocilizumab is increasing [16].
The case shows a patient with hyperinflammation and COVID-
19 with an underlying diagnosis of HH that was treated with Ana-
kinra, that went on to develop hepatotoxicity, possibly as a result.
Interestingly another patient we reported with COVID-19-
associated HLH also developed deranged liver enzymes which
appeared to respond to a change in antibiotics [17]. In a small
study of 80 adults looking at characteristics with secondary HLH
deranged liver function tests were identified in 70 (87%) of patients
[18]. Anakinra is a recombinant IL-1 receptor antagonist and has
previously been evaluated as a method to counteract the cytokine
storm observed in severe sepsis and septic shock. As IL-1 serum
concentrations have been shown to be significantly increased in
patients with COVID-19 compared to healthy controls it is thought
that Anakinra may benefit these patients [19]. However, there is
limited data about the toxicity of Anakinra in COVID-19 patients.
The reason for the deterioration of the patient’s liver function is
likely multifactorial due to HH, medication and part of HLH
syndrome.
High dose intravenous and then oral steroids were used to treat
a potential haematological malignancy in this man, and were
administered before respiratory deterioration and oxygen depen-
dence. Recently the RECOVERY trial announced there was signifi-
cant benefit in COVID-19 patients who required respiratory
support being prescribed dexamethasone. Initial data indicates
one death being prevented by treatment of around eight ventilated
patients or around twenty-five patients requiring oxygen alone
[20]. There was no benefit in the use of dexamethasone in patients
not requiring oxygen, and a potential signal of harm. A meta-6
analysis by WHO of clinical trials involving corticosteroids in
COVID-19 is underway and eagerly awaited.
Whilst this complex case did initially carry some clinical uncer-
tainties that were not allayed until post-mortem, one aspect that
was evidently clear was the bi-phasic nature of his illness. Rela-
tively mild symptoms of COVID-19 were observed at presentation
and clinical stability, with little or no oxygen requirements, contin-
ued throughout the initial stages of his admission. Week three of
his symptoms, however, heralded a dramatic and irreversible dete-
rioration that resulted in acute respiratory failure and was the ulti-
mate cause of his death. This pattern has been repeatedly observed
as one subtype of the COVID-19 clinical syndrome [21]. It is felt to
signify that effective host control of the virus in the initial stages of
infection is crucial to preventing progression towards severe dis-
ease [21]. We propose that a degree of immune dysfunction sec-
ondary to HH impeded this response. Excess intracellular and
circulating iron may have provided ample material to fuel explo-
sive viral replication in the presence of an already dysregulated
immune system, subsequently provoking a hyperinflammatory
HLH-like state. The potential benefits or harms of high dose ster-
oids in this situation, combined with emerging RECOVERY trial
data is unclear.
A definitive link between this man’s underlying HH and the
observed hyperinflammatory, bi-phasic COVID-19 illness is not
certain. As far as we can tell at the time of writing there is no cur-
rent publication that outlines such a link. It is the opinion of our
group, however, that there is sufficient evidence existing in current
literature relating to the effects of hereditary haemochromatosis
on other viral infections and immune function to infer that a
potential pathological association may exist, and further investiga-
tion is required.
Fig. 5. Microscopic appearances of vascular structures from various tissue samples at post-mortem. (a and b) Histological changes in the kidneys with fibrin thrombi in
peritubular capillaries (Martius Scarlet Blue) and in glomerular capillaries (haematoxylin and eosin stain) respectively. (c and d) Histological changes in splenic blood vessel
showing intimal haemorrhage and lymphocytic infiltration of uncertain significance (haematoxylin and eosin stain) respectively.
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